Resoundant, Inc.

Resoundant, Inc. develops and delivers Magnetic Resonance Elastography (MRE), a quantitative, noninvasive imaging technology for liver fibrosis assessment and staging of liver disease. MRE converts MRI data into precise, reproducible measurements of tissue stiffness using advanced computational algorithms to generate standardized biomarkers, offering an FDA-cleared alternative to Fibroscan transient elastography and shear wave ultrasound elastography. The technology is deployed as an upgrade to existing MRI systems and is available at thousands of radiology and imaging centers globally. MRE provides consistent, operator-independent, scanner-independent clinical assessment and has been accepted into the FDA Biomarker Qualification Program as a Reasonably Likely Surrogate Endpoint for MASH (Metabolic Associated Fatty Liver Disease) clinical trials. The company serves healthcare systems, radiology centers, and imaging facilities worldwide seeking noninvasive, quantitative liver disease assessment capabilities.